Raymond James Financial Services Advisors Inc. lifted its position in shares of Antares Pharma Inc (NASDAQ:ATRS) by 34.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 180,666 shares of the specialty pharmaceutical company’s stock after buying an additional 46,766 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Antares Pharma were worth $360,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. State Board of Administration of Florida Retirement System increased its stake in shares of Antares Pharma by 95.0% during the third quarter. State Board of Administration of Florida Retirement System now owns 59,413 shares of the specialty pharmaceutical company’s stock worth $192,000 after purchasing an additional 28,940 shares during the period. Voya Investment Management LLC bought a new position in shares of Antares Pharma during the second quarter worth approximately $210,000. The Manufacturers Life Insurance Company increased its stake in shares of Antares Pharma by 1,188.2% during the second quarter. The Manufacturers Life Insurance Company now owns 121,633 shares of the specialty pharmaceutical company’s stock worth $392,000 after purchasing an additional 112,191 shares during the period. California State Teachers Retirement System bought a new position in shares of Antares Pharma during the second quarter worth approximately $820,000. Finally, TIAA FSB bought a new position in shares of Antares Pharma during the fourth quarter worth approximately $977,000. Institutional investors own 35.36% of the company’s stock.
ATRS has been the topic of a number of recent research reports. BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. ValuEngine lowered Antares Pharma from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, HC Wainwright set a $4.00 target price on Antares Pharma and gave the stock a “buy” rating in a research note on Wednesday, March 14th. One research analyst has rated the stock with a sell rating, four have issued a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $3.94.
Shares of Antares Pharma stock opened at $2.43 on Monday. The stock has a market capitalization of $381.00, a P/E ratio of -24.30 and a beta of 0.23. Antares Pharma Inc has a 12-month low of $1.58 and a 12-month high of $4.09. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.94 and a current ratio of 3.53.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Tuesday, March 13th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. The business had revenue of $14.00 million for the quarter, compared to the consensus estimate of $15.44 million. Antares Pharma had a negative return on equity of 44.29% and a negative net margin of 30.71%. The business’s quarterly revenue was down 1.4% compared to the same quarter last year. analysts forecast that Antares Pharma Inc will post -0.07 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Raymond James Financial Services Advisors Inc. Purchases 46,766 Shares of Antares Pharma Inc (ATRS)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/19/raymond-james-financial-services-advisors-inc-purchases-46766-shares-of-antares-pharma-inc-atrs.html.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Want to see what other hedge funds are holding ATRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Antares Pharma Inc (NASDAQ:ATRS).
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.